Impact of Tumor VEGF Expression on Chemotherapy and Antiangiogenic Therapy in Ovarian Cancer
Author Information
Author(s): David O. Holtz, Robert T. Krafty, Alisha Mohamed-Hadley, Lin Zhang, Ioannis Alagkiozidis, Benjamin Leiby, Wensheng Guo, Phyllis A. Gimotty, George Coukos
Primary Institution: University of Pennsylvania
Hypothesis
Does tumor VEGF expression influence the efficacy of low-dose chemotherapy combined with antiangiogenic therapy?
Conclusion
Tumor VEGF expression significantly affects the interactions between low-dose chemotherapy and antiangiogenic therapy, with low VEGF tumors benefiting more from the combination.
Supporting Evidence
- Low-dose paclitaxel showed additive effects with antiangiogenic therapy in tumors with low VEGF expression.
- High VEGF expression in tumors led to antagonistic interactions with low-dose chemotherapy.
- Statistical modeling revealed significant differences in tumor response based on VEGF levels.
Takeaway
This study shows that some tumors respond better to a mix of chemotherapy and anti-cancer drugs if they have low levels of a protein called VEGF.
Methodology
The study used ID8 and ID8-Vegf mouse models to analyze the effects of low-dose paclitaxel and SU5416 on tumor growth and microvascular density.
Potential Biases
Potential bias due to the use of a single mouse model and the specific conditions of the experiments.
Limitations
The study used a flank model rather than an orthotopic tumor model, which may limit the applicability of the findings to human ovarian cancer.
Participant Demographics
Female C57BL/6 mice aged six to eight weeks were used in the experiments.
Statistical Information
P-Value
0.0029
Confidence Interval
95% Bayesian confidence intervals
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website